Postprandial Dysmetabolism
PPDysMet
1 other identifier
interventional
34
1 country
1
Brief Summary
Type 2 diabetes (T2D) is a common disease associated with multiple complications and an increased risk of cardiovascular morbidity and mortality. Also, it is a heavy economical burden on society. 1st degree relatives of patients with T2D have an increased risk of developing T2D. This risk can be modified by the ingested diet: a traditional north European diet rich in saturated fat increases the risk, while a Mediterranean diet rich in monounsaturated fat protects from development of T2D and cardiovascular disease. T2D is a part of the metabolic syndrome consisting of T2D, hypertension, adipositas, dyslipidemia and steatosis. The pathogenesis of the metabolic syndrome is partly explained by fasting dyslipidemia, postprandial dysmetabolism (derangement of lipid and carbohydrate metabolism) and impaired metabolic flexibility. Partly, it can be explained by a chronic low-grade inflammation in peripheral tissue. The dysmetabolism and the inflammation are correlating entities exerting their influence through common biochemical pathways. This is established in patients with T2D, but sparsely studied in healthy relatives of patients with T2D. In this project, the investigators will study postprandial dysmetabolism, inflammation, oxidative stress, adipocytokines, incretins, appetite regulating hormones and the expression of the genes involved in above mentioned. We will compare healthy 1st degree relatives of patients with T2D with healthy controls with no family history of T2D and look into differences in the response to meal stimulation with respectively saturated and monounsaturated fat. The subjects will be thoroughly examined with a hyperinsulinaemic euglycaemic clamp and a DEXA scan. Before and after the meal stimulation, we will perform calorimetry (in order to determine the metabolic rates), take blood samples and perform muscle and fat tissue biopsies. The biopsies will be used for studies of a vast number of genes. The project will give us new valuable knowledge about the interaction between the intermediate metabolism and the innate immune system and the early pre-diabetic changes in the 1st degree relatives of patients with T2D. In the long run, the project will contribute to improving our guidance and treatment of persons at risk of developing T2D.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable type-2-diabetes-mellitus
Started Jan 2009
Typical duration for not_applicable type-2-diabetes-mellitus
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 19, 2008
CompletedFirst Posted
Study publicly available on registry
December 22, 2008
CompletedStudy Start
First participant enrolled
January 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2011
CompletedMarch 8, 2011
December 1, 2008
1.9 years
December 19, 2008
March 7, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incremental AUC og the triglyceride response
6 hrs
Secondary Outcomes (1)
Gene expression of genes involved in lipid metabolism and inflammation
6 hrs
Study Arms (2)
1
EXPERIMENTALRelatives to patients with type 2 diabetes.
2
ACTIVE COMPARATORControls with no family history of type 2 diabetes.
Interventions
Eligibility Criteria
You may qualify if:
- Relatives: Minimum 2 1st degree relatives with type 2 diabetes or 1 one 1st degree relative with type 2 diabetes and history of gestational diabetes.
- Controls: No family history of type 2 diabetes and fasting blood glucose \<6.0 mM.
You may not qualify if:
- Cardiovascular, renal or endocrine disease.
- Treatment with steroids.
- Psychiatric history.
- Abuse of alcohol or narcotics.
- Smoking.
- Pregnancy or breast-feeding.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aarhus University Hospitallead
- Diabetesforeningencollaborator
Study Sites (1)
Aarhus University Hospital
Aarhus, 8000, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 19, 2008
First Posted
December 22, 2008
Study Start
January 1, 2009
Primary Completion
December 1, 2010
Study Completion
August 1, 2011
Last Updated
March 8, 2011
Record last verified: 2008-12